Cell Reports · 2015 · 147 citations · 49 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyInnate ImmunityCancer ImmunotherapyCytokine BiologyDendritic Cell BiologyInflammatory SignalingInnate Immune Signaling PathwaysToll-like ReceptorsCell Surface Recognition ReceptorsDendritic Cell SignalingTherapeutic Target IdentificationToll-like Receptor SignalingToll-like Receptor-mediated Cytokine InductionToll-like Receptors In CancerTumor ImmunogenicityTumor-associated Inflammation
Although dendritic cell (DC) dysfunction in cancer is a well-recognized consequence of cancer-associated inflammation that contributes to immune evasion, the mechanisms that drive this process remain elusive. Here, we show the critical importance of tumor-derived TLR2 ligands in the generation of immunosuppressive IL-10-producing human and mouse DCs. TLR2 ligation induced two parallel synergistic processes that converged to activate STAT3: stimulation of autocrine IL-6 and IL-10 and upregulation of their respective cell surface receptors, which lowered the STAT3 activation threshold. We identified versican as a soluble tumor-derived factor that activates TLR2 in DCs. TLR2 blockade in vivo improved intra-tumor DC immunogenicity and enhanced the efficacy of immunotherapy. Our findings provide a basis for understanding the molecular mechanisms of DC dysfunction in cancer and identify TLR2 as a relevant therapeutic target to improve cancer immunotherapy.
49
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Jérôme Galon, Anne Costes, Fátima Sánchez‐Cabo et al. · Science · 2006 · 6.5K citations
Medicine, Immunology, Oncology +17
Role of Adaptor TRIF in the MyD88-Independent Toll-Like Receptor Signaling Pathway
Masahiro Yamamoto, Shintaro Sato, Hiroaki Hemmi et al. · Science · 2003 · 3.2K citations
Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
Noriho Iida, Amiran Dzutsev, Charles A. Stewart et al. · Science · 2013 · 2.2K citations · Full text
Medicine, Immunology, Oncology +17